MDxHealth « Terug naar discussie overzicht

MDxHealth nieuws 2014

5.395 Posts, Pagina: « 1 2 3 4 5 6 ... 62 63 64 65 66 67 68 69 70 71 72 ... 266 267 268 269 270 » | Laatste

Omlaag ↓

[verwijderd] 27 maart 2014 16:09

Ik had al zo'n flauw vermoeden dat de handel bij Exact Sciences is stilgelegd tot er meer bekend is.

[verwijderd] 27 maart 2014 17:38

Nu nog even een paar uur wachten op nieuws uit USA..

[verwijderd] 27 maart 2014 17:40

Iedereen is het wachten moe.
Had beter voor een deel in Aperam kunnen blijven zitten de laatste twee weken.
Hopelijk wordt het wachten morgen beloont.

[verwijderd] 27 maart 2014 18:04

waarom wordt de handel stilgelegd? Uit angst? Of kunnen er teveel fluctuaties komen? Als dat gedaan wordt, verwacht men touchaardig wat nieuws met grote invloed lijkt me?

Bart

Nel 27 maart 2014 18:12

the panel vote which happens at 4:30 pm eastern

[verwijderd] 27 maart 2014 19:33

quote:
sam en moos schreef op 27 maart 2014 17:40:
Iedereen is het wachten moe.
Had beter voor een deel in Aperam kunnen blijven zitten de laatste twee weken.
Hopelijk wordt het wachten morgen beloont.

Het wachten moe ? Lekkere LT belegger ben jij
Lt belegger gaat voor minimaal 1-3 jaar

[verwijderd] 27 maart 2014 19:58

www.fda.gov/downloads/advisorycommitt...

cruson 27 maart 2014 20:30

Prima nieuws.

fda panel votes unanimously to recommend approval of Cologuard colon cancer screening test from client Exact Sciences

cruson 27 maart 2014 20:33

Via Twitter

@CaptainFuture__: $EXAS ADVISERS TO US FDA VOTE 10-0 THAT BENEFITS OUTWEIGH RISKS FOR EXACT SCIENCES DNA-BASED COLON CANCER TEST

Pelikapuntzak 27 maart 2014 20:34

quote:
cruson schreef op 27 maart 2014 20:30:
Prima nieuws.

fda panel votes unanimously to recommend approval of Cologuard colon cancer screening test from client Exact Sciences

Hehe........geweldig nieuws bedankt cruson. Ben je snel achtergekomen.
Zie het al Twitter.

Bahassie 27 maart 2014 20:41

quote:
Pelikapuntzak schreef op 27 maart 2014 20:34:
[...]

Hehe........geweldig nieuws bedankt cruson. Ben je snel achtergekomen.
Zie het al Twitter.

Toch eerder dan 2200 LT... goed nieuws... dus FRZ morgen.. of handelen als een malle?

effegenoeg 27 maart 2014 20:50

Hold them tight is my device!

cruson 27 maart 2014 21:01

Exact Sciences Announces FDA Advisory Committee Unanimously Recommends Approval of Cologuard
« Previous Releases
First of its Kind Stool-based DNA Screening Test for Colorectal Cancer

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard®, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test.

"We are pleased the Committee strongly supported Cologuard's approval," said Kevin T. Conroy, chairman and chief executive of Exact Sciences. "We look forward to continuing our work with the FDA to complete its review of Cologuard and remain committed to addressing the growing unmet needs in colorectal cancer screening. We thank the FDA and its advisory committee for its careful consideration of Cologuard. We also appreciate the opportunity to participate in the innovative FDA/CMS parallel review program. "

In the company's 10,000-patient, 90-site DeeP-C pivotal trial—one of the most extensive colorectal cancer screening studies ever conducted in the United States—Exact Sciences' Cologuard found 92.3% of colorectal cancer in average risk patients based on a combination of DNA and hemoglobin markers. Exact Sciences submitted the final module of its PMA for Cologuard on June 7, 2013, and the application includes data from that study, which was published online on March 19, 2014, in the New England Journal of Medicine. The peer-reviewed study, "Multi-target Stool DNA Testing for Colorectal-Cancer Screening" will also appear in the journal's April 3, 2014 print issue.

The FDA is not bound by the recommendation of its advisory committee, but will consider the committee's guidance as it evaluates the Cologuard PMA.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company's website at www.exactsciences.com.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results of our pivotal clinical trial, expectations concerning our ability to secure FDA approval of our Cologuard test, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Exact Sciences Corp.
Cara Tucker
Manager, Corporate Communications
614-302-5622

Source: Exact Sciences Corp.

News Provided by Acquire Media

Bahassie 27 maart 2014 21:01

quote:
effegenoeg schreef op 27 maart 2014 20:50:
Hold them tight is my device!

Oh ja.. Cker.. das ook t plan. Ik hoop alleen dat er morgen ook werkelijk gebroken gaat worden en dat we niet in een arcelor scenario terrecht komen

Pelikapuntzak 27 maart 2014 21:02

quote:
effegenoeg schreef op 27 maart 2014 20:50:
Hold them tight is my device!

Groot gelijk, in rap tempo naar €10 en hoger. We zullen Genfit nog een poepie laten ruiken. Alle zittenblijvers proficiat en succes morgen. Al zal Exas meer nog dan wij profiteren.

cruson 27 maart 2014 21:03

Op 3 punten gescoord Kan niet beter

a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard®, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test.

[verwijderd] 27 maart 2014 21:05

Wow gefeliciteerd Exact Science / MdxHealth en alle toekomstige patiënten
Super . Dat wordt knallen de komende jaren . Op naar de volgende goedgekeurde licentie ..

[verwijderd] 27 maart 2014 21:08

quote:
bioscience schreef op 27 maart 2014 21:05:
Wow gefeliciteerd Exact Science / MdxHealth en alle toekomstige patiënten
Super . Dat wordt knallen de komende jaren . Op naar de volgende goedgekeurde licentie ..

Vergeet alle Lt beleggers te feliciteren .

Geschatte opening morgen ?

Pelikapuntzak 27 maart 2014 21:10

Koersadvies Petercam is 5.30 die mogen ze morgen gelijk verhogen.

[verwijderd] 27 maart 2014 21:10

Ik neem aan ook een persbericht van MDX morgenochtend .

5.395 Posts, Pagina: « 1 2 3 4 5 6 ... 62 63 64 65 66 67 68 69 70 71 72 ... 266 267 268 269 270 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	1 jan 0001
Koers	0,000
Verschil	0,000 (0,00%)
Hoog	0,000
Laag	0,000
Volume	0
Volume gemiddeld	0
Volume gisteren	0

nieuws

13 mei	Beursupdate: AEX op Wall Street
13 mei	Wall Street verdeeld gesloten
13 mei	Olieprijzen hoger gesloten
13 mei	Aandeelhouders Fagron akkoord met all...
13 mei	Wall Street blijft dicht bij huis
13 mei	Voorzichtige weekstart Europese beurzen
13 mei	Slotcall: AEX stijgt nipt, maar Theon...
13 mei	Euronext meldt licht hogere volumes
13 mei	AEX scherpt record iets verder aan
13 mei	Bloomberg: Nederlandse belasting op a...	4

Meer ››